Clinical trial
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS…
NCT00089245 · Y-mAbs Therapeutics, Industry · Terminated
Key facts
| NCT number | NCT00089245 |
|---|---|
| Title | Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer |
| Official title | Phase I Study Of Intrathecal Radioimmunotherapy Using I-8H9 For Central Nervous System/Leptomeningeal Neoplasms |
| Lead sponsor | Y-mAbs Therapeutics, Industry |
| Collaborators | Memorial Sloan Kettering Cancer Center |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma |
| Intervention type | Drug |
| Interventions | Iodine I 131 MOAB 8H9 |
| Enrollment | 177 |
| Start date | Feb 5, 2004 |
| Primary completion | Feb 2, 2022 |
| Completion | Feb 2, 2022 |
| First posted | Aug 5, 2004 |
| Last update posted | Dec 26, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: